The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden

Giuseppe Boriani, Gregory Y.H. Lip, Renato Pietro Ricci, Alessandro Proclemer, Maurizio Landolina, Maurizio Lunati, Luigi Padeletti, Gabriele Zanotto, Giulio Molon, Mauro Biffi, Roberto Rordorf, Fabio Quartieri, Maurizio Gasparini

Research output: Contribution to journalArticle

Abstract

In patients with atrial fibrillation (AF), risk stratification for stroke is the cornerstone of clinical decision making.1 In patients with AF female gender has emerged as a stroke risk factor in many studies and metaanalyses2 and has been included in the CHA2DS2-VASc score, which is the stroke risk stratification scheme recommended in most guidelines.1,2 However, there is an age dependency to stroke risk in females, and there is no significant increase in the overall risk of stroke in female patients age<65 years with lone AF.2 The precise reasons why female gender increases the thromboembolic risk are not completely known.3,4 The relationship between stroke and AF burden has recently been the object of growing interest, since AF burden provides an overall assessment of the amount of time spent in AF, and has been associated with an increased risk of stroke.5-9 Even if clinical risk stratification is based on clinical factors, data from patients implanted with a cardiac implantable electrical device (CIED) providing continuous monitoring of the atrial rhythm showed that the maximum daily AF burden is associated with an increased risk of ischaemic stroke or transient ischemic attack (TIA), even after adjustment for oral anticoagulants use and the CHADS2 score.10,11 This suggests that measuring daily AF burden may have important clinical relevance8 and supports the search for specific thresholds of AF burden associated with a substantial increase in the risk of ischaemic stroke.6,7,11 Indeed, AF burden can improve the predictive value of clinical risk scores, such as CHADS2, for stroke and thromboembolism.7 In this analysis, based on data collected in a prospective observational research of patient with a CIED we tested the hypothesis that the increased thromboembolic risk in female patients may be related to a higher burden of AF, by comparing the maximum AF daily burden inmen and women during long-term follow-up. Methods Project design and patient population Patients participating to the Italian ClinicalServiceVR Project [ClinicalTrials.gov Identifier: NCT01007474],12 a national medical care project aiming to improve the quality of diagnostic and therapeutic strategies through the use of implantable cardiac devices in clinical practice, were considered for the present analysis. The project consists of a shared environment for prospective collection, management, analysis and reporting of data from patients in whomMedtronic devices have been implanted. In the Italian ClinicalServiceVR Project, patients are prospectively followed by participating centres according to clinical practice and guidelines through standard in-hospital visits. An independent scientific committee of physicians prospectively identifies key clinical questions on a yearly basis for analysis and publication. A charter assigns the ownership of data to the centres and governs the conduct and relationship of the scientific committee and Medtronic. The project was approved by each site's Medical Ethics Committee orMedical Director and conforms to the principles outlined in the Declaration of Helsinki. Each patient provided informed consent for data collection and analysis. For the present analysis, patients were included if they had a CIED with an atrial lead, had not permanent atrial tachyarrhythmia/atrial fibrillation (AT/AF), had a clinical follow-up duration of at least 183 days or more, and had device data continuously stored during the observation period.

Original languageEnglish
Pages (from-to)1767-1775
Number of pages9
JournalEuropace
Volume19
Issue number11
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Transient Ischemic Attack
Atrial Fibrillation
Stroke
Equipment and Supplies
Helsinki Declaration
Ethics Committees
Medical Ethics
Ownership
Informed Consent
Practice Guidelines
Tachycardia
Anticoagulants
Publications
Research Design
Observation

Keywords

  • Anticoagulation
  • Atrial fibrillation
  • Implantable defibrillator
  • Pacemaker
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden. / Boriani, Giuseppe; Lip, Gregory Y.H.; Ricci, Renato Pietro; Proclemer, Alessandro; Landolina, Maurizio; Lunati, Maurizio; Padeletti, Luigi; Zanotto, Gabriele; Molon, Giulio; Biffi, Mauro; Rordorf, Roberto; Quartieri, Fabio; Gasparini, Maurizio.

In: Europace, Vol. 19, No. 11, 01.11.2017, p. 1767-1775.

Research output: Contribution to journalArticle

Boriani, Giuseppe ; Lip, Gregory Y.H. ; Ricci, Renato Pietro ; Proclemer, Alessandro ; Landolina, Maurizio ; Lunati, Maurizio ; Padeletti, Luigi ; Zanotto, Gabriele ; Molon, Giulio ; Biffi, Mauro ; Rordorf, Roberto ; Quartieri, Fabio ; Gasparini, Maurizio. / The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden. In: Europace. 2017 ; Vol. 19, No. 11. pp. 1767-1775.
@article{2a0cb37a76b04ebf9e121924929d7ea2,
title = "The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden",
abstract = "In patients with atrial fibrillation (AF), risk stratification for stroke is the cornerstone of clinical decision making.1 In patients with AF female gender has emerged as a stroke risk factor in many studies and metaanalyses2 and has been included in the CHA2DS2-VASc score, which is the stroke risk stratification scheme recommended in most guidelines.1,2 However, there is an age dependency to stroke risk in females, and there is no significant increase in the overall risk of stroke in female patients age<65 years with lone AF.2 The precise reasons why female gender increases the thromboembolic risk are not completely known.3,4 The relationship between stroke and AF burden has recently been the object of growing interest, since AF burden provides an overall assessment of the amount of time spent in AF, and has been associated with an increased risk of stroke.5-9 Even if clinical risk stratification is based on clinical factors, data from patients implanted with a cardiac implantable electrical device (CIED) providing continuous monitoring of the atrial rhythm showed that the maximum daily AF burden is associated with an increased risk of ischaemic stroke or transient ischemic attack (TIA), even after adjustment for oral anticoagulants use and the CHADS2 score.10,11 This suggests that measuring daily AF burden may have important clinical relevance8 and supports the search for specific thresholds of AF burden associated with a substantial increase in the risk of ischaemic stroke.6,7,11 Indeed, AF burden can improve the predictive value of clinical risk scores, such as CHADS2, for stroke and thromboembolism.7 In this analysis, based on data collected in a prospective observational research of patient with a CIED we tested the hypothesis that the increased thromboembolic risk in female patients may be related to a higher burden of AF, by comparing the maximum AF daily burden inmen and women during long-term follow-up. Methods Project design and patient population Patients participating to the Italian ClinicalServiceVR Project [ClinicalTrials.gov Identifier: NCT01007474],12 a national medical care project aiming to improve the quality of diagnostic and therapeutic strategies through the use of implantable cardiac devices in clinical practice, were considered for the present analysis. The project consists of a shared environment for prospective collection, management, analysis and reporting of data from patients in whomMedtronic devices have been implanted. In the Italian ClinicalServiceVR Project, patients are prospectively followed by participating centres according to clinical practice and guidelines through standard in-hospital visits. An independent scientific committee of physicians prospectively identifies key clinical questions on a yearly basis for analysis and publication. A charter assigns the ownership of data to the centres and governs the conduct and relationship of the scientific committee and Medtronic. The project was approved by each site's Medical Ethics Committee orMedical Director and conforms to the principles outlined in the Declaration of Helsinki. Each patient provided informed consent for data collection and analysis. For the present analysis, patients were included if they had a CIED with an atrial lead, had not permanent atrial tachyarrhythmia/atrial fibrillation (AT/AF), had a clinical follow-up duration of at least 183 days or more, and had device data continuously stored during the observation period.",
keywords = "Anticoagulation, Atrial fibrillation, Implantable defibrillator, Pacemaker, Stroke",
author = "Giuseppe Boriani and Lip, {Gregory Y.H.} and Ricci, {Renato Pietro} and Alessandro Proclemer and Maurizio Landolina and Maurizio Lunati and Luigi Padeletti and Gabriele Zanotto and Giulio Molon and Mauro Biffi and Roberto Rordorf and Fabio Quartieri and Maurizio Gasparini",
year = "2017",
month = "11",
day = "1",
doi = "10.1093/europace/euw333",
language = "English",
volume = "19",
pages = "1767--1775",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden

AU - Boriani, Giuseppe

AU - Lip, Gregory Y.H.

AU - Ricci, Renato Pietro

AU - Proclemer, Alessandro

AU - Landolina, Maurizio

AU - Lunati, Maurizio

AU - Padeletti, Luigi

AU - Zanotto, Gabriele

AU - Molon, Giulio

AU - Biffi, Mauro

AU - Rordorf, Roberto

AU - Quartieri, Fabio

AU - Gasparini, Maurizio

PY - 2017/11/1

Y1 - 2017/11/1

N2 - In patients with atrial fibrillation (AF), risk stratification for stroke is the cornerstone of clinical decision making.1 In patients with AF female gender has emerged as a stroke risk factor in many studies and metaanalyses2 and has been included in the CHA2DS2-VASc score, which is the stroke risk stratification scheme recommended in most guidelines.1,2 However, there is an age dependency to stroke risk in females, and there is no significant increase in the overall risk of stroke in female patients age<65 years with lone AF.2 The precise reasons why female gender increases the thromboembolic risk are not completely known.3,4 The relationship between stroke and AF burden has recently been the object of growing interest, since AF burden provides an overall assessment of the amount of time spent in AF, and has been associated with an increased risk of stroke.5-9 Even if clinical risk stratification is based on clinical factors, data from patients implanted with a cardiac implantable electrical device (CIED) providing continuous monitoring of the atrial rhythm showed that the maximum daily AF burden is associated with an increased risk of ischaemic stroke or transient ischemic attack (TIA), even after adjustment for oral anticoagulants use and the CHADS2 score.10,11 This suggests that measuring daily AF burden may have important clinical relevance8 and supports the search for specific thresholds of AF burden associated with a substantial increase in the risk of ischaemic stroke.6,7,11 Indeed, AF burden can improve the predictive value of clinical risk scores, such as CHADS2, for stroke and thromboembolism.7 In this analysis, based on data collected in a prospective observational research of patient with a CIED we tested the hypothesis that the increased thromboembolic risk in female patients may be related to a higher burden of AF, by comparing the maximum AF daily burden inmen and women during long-term follow-up. Methods Project design and patient population Patients participating to the Italian ClinicalServiceVR Project [ClinicalTrials.gov Identifier: NCT01007474],12 a national medical care project aiming to improve the quality of diagnostic and therapeutic strategies through the use of implantable cardiac devices in clinical practice, were considered for the present analysis. The project consists of a shared environment for prospective collection, management, analysis and reporting of data from patients in whomMedtronic devices have been implanted. In the Italian ClinicalServiceVR Project, patients are prospectively followed by participating centres according to clinical practice and guidelines through standard in-hospital visits. An independent scientific committee of physicians prospectively identifies key clinical questions on a yearly basis for analysis and publication. A charter assigns the ownership of data to the centres and governs the conduct and relationship of the scientific committee and Medtronic. The project was approved by each site's Medical Ethics Committee orMedical Director and conforms to the principles outlined in the Declaration of Helsinki. Each patient provided informed consent for data collection and analysis. For the present analysis, patients were included if they had a CIED with an atrial lead, had not permanent atrial tachyarrhythmia/atrial fibrillation (AT/AF), had a clinical follow-up duration of at least 183 days or more, and had device data continuously stored during the observation period.

AB - In patients with atrial fibrillation (AF), risk stratification for stroke is the cornerstone of clinical decision making.1 In patients with AF female gender has emerged as a stroke risk factor in many studies and metaanalyses2 and has been included in the CHA2DS2-VASc score, which is the stroke risk stratification scheme recommended in most guidelines.1,2 However, there is an age dependency to stroke risk in females, and there is no significant increase in the overall risk of stroke in female patients age<65 years with lone AF.2 The precise reasons why female gender increases the thromboembolic risk are not completely known.3,4 The relationship between stroke and AF burden has recently been the object of growing interest, since AF burden provides an overall assessment of the amount of time spent in AF, and has been associated with an increased risk of stroke.5-9 Even if clinical risk stratification is based on clinical factors, data from patients implanted with a cardiac implantable electrical device (CIED) providing continuous monitoring of the atrial rhythm showed that the maximum daily AF burden is associated with an increased risk of ischaemic stroke or transient ischemic attack (TIA), even after adjustment for oral anticoagulants use and the CHADS2 score.10,11 This suggests that measuring daily AF burden may have important clinical relevance8 and supports the search for specific thresholds of AF burden associated with a substantial increase in the risk of ischaemic stroke.6,7,11 Indeed, AF burden can improve the predictive value of clinical risk scores, such as CHADS2, for stroke and thromboembolism.7 In this analysis, based on data collected in a prospective observational research of patient with a CIED we tested the hypothesis that the increased thromboembolic risk in female patients may be related to a higher burden of AF, by comparing the maximum AF daily burden inmen and women during long-term follow-up. Methods Project design and patient population Patients participating to the Italian ClinicalServiceVR Project [ClinicalTrials.gov Identifier: NCT01007474],12 a national medical care project aiming to improve the quality of diagnostic and therapeutic strategies through the use of implantable cardiac devices in clinical practice, were considered for the present analysis. The project consists of a shared environment for prospective collection, management, analysis and reporting of data from patients in whomMedtronic devices have been implanted. In the Italian ClinicalServiceVR Project, patients are prospectively followed by participating centres according to clinical practice and guidelines through standard in-hospital visits. An independent scientific committee of physicians prospectively identifies key clinical questions on a yearly basis for analysis and publication. A charter assigns the ownership of data to the centres and governs the conduct and relationship of the scientific committee and Medtronic. The project was approved by each site's Medical Ethics Committee orMedical Director and conforms to the principles outlined in the Declaration of Helsinki. Each patient provided informed consent for data collection and analysis. For the present analysis, patients were included if they had a CIED with an atrial lead, had not permanent atrial tachyarrhythmia/atrial fibrillation (AT/AF), had a clinical follow-up duration of at least 183 days or more, and had device data continuously stored during the observation period.

KW - Anticoagulation

KW - Atrial fibrillation

KW - Implantable defibrillator

KW - Pacemaker

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85034866632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034866632&partnerID=8YFLogxK

U2 - 10.1093/europace/euw333

DO - 10.1093/europace/euw333

M3 - Article

AN - SCOPUS:85034866632

VL - 19

SP - 1767

EP - 1775

JO - Europace

JF - Europace

SN - 1099-5129

IS - 11

ER -